TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22108775

Group type: EXPERIMENTAL
Intervention: Rabeprazole 40 mg once daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily
Number of subjects: 24
Study: 19614621

Group type: EXPERIMENTAL
Intervention: Masitinib (3, 4.5, and 6 mg/kg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Masitinib
Number of subjects: 44
Study: 17968637

Group type: EXPERIMENTAL
Intervention: Tibetan medicine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Misoprostol
Number of subjects: 0
Study: 15311147

Group type: EXPERIMENTAL
Intervention: Telmisartan (40-80 mg)
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Telmisartan (40-80 mg) after missed dose
Number of subjects: 877

Group type: COMPARATOR
Intervention: Valsartan (80-160 mg)
Number of subjects: 877

Group type: COMPARATOR
Intervention: Valsartan (80-160 mg) after missed dose
Number of subjects: 877
Study: 12074234

Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer cement loaded with 3% sodium fluoride
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer cement loaded with 2% sodium fluoride
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer cement loaded with 1% sodium fluoride
Number of subjects: 75

Group type: COMPARATOR
Intervention: Non-loaded resin-modified glass-ionomer cement
Number of subjects: 75

Group type: COMPARATOR
Intervention: Non-fluoridated resin-based composite
Number of subjects: 75
Study: 9501889

Group type: EXPERIMENTAL
Intervention: Sertraline during the luteal phase
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo during the luteal phase
Number of subjects: 31
Study: 8478238

Group type: EXPERIMENTAL
Intervention: 4 fractions of 2.5 Gy per week
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 5 fractions of 2 Gy per week
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 32
Study: 3093915

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Enteral nutrition (NG)
Number of subjects: 45
Study: 31645364

Group type: EXPERIMENTAL
Intervention: Use of a web-based decision support tool for antidepressant treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 29709378

Group type: EXPERIMENTAL
Intervention: Redistributed inhomogeneous boosting to the GTV subvolume (FDG-SUV > 50% SUVmax)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Homogeneous boosting to the primary tumor
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 82
Study: 26842902

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily for CrCl ≥ 50 ml/min or 7.5 mg once daily for CrCl ≥ 30 ml/min and < 50 ml/min for 45 days
Number of subjects: 8000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8000
Study: 24576226

Group type: EXPERIMENTAL
Intervention: Highly purified menotropin (HP-hMG)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Recombinant follicle-stimulating hormone (rFSH)
Number of subjects: 343
Study: 23302475

Group type: EXPERIMENTAL
Intervention: MoodGYM (self‐directed Internet‐delivered cognitive‐behavioral skills training tool)
Number of subjects: 3070

Group type: COMPARATOR
Intervention: Control group (waiting-list control)
Number of subjects: 3070
Study: 20206060

Group type: EXPERIMENTAL
Intervention: Electrostimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (traditional exercise training)
Number of subjects: 0
Study: 17399674

Group type: EXPERIMENTAL
Intervention: Clariflex IOL with OptiEdge (sharp posterior optic edge)
Number of subjects: 52

Group type: COMPARATOR
Intervention: SI40 IOL (round edges)
Number of subjects: 52
Study: 15769490

Group type: COMPARATOR
Intervention: Children with ASD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Typically developing children
Number of subjects: 0
Study: 11939913

Group type: EXPERIMENTAL
Intervention: A-line Arx Index (AAI)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Auditory Evoked Potentials (AEP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Modified Observers Assessment of Alertness and Sedation Scale (MOAAS)
Number of subjects: 24
Study: 9499185

Group type: EXPERIMENTAL
Intervention: Mitomycin C, epirubicin and cisplatin (MEP)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Mitomycin C alone (MITOC)
Number of subjects: 84
Study: 7747227

Group type: EXPERIMENTAL
Intervention: Computed Tomography
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Number of subjects: 80

Group type: COMPARATOR
Intervention: Myelography
Number of subjects: 80
Study: 2144819

Group type: EXPERIMENTAL
Intervention: Flutamide (FLU)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cyproterone acetate (CPA)
Number of subjects: 100
Study: 6118522

Group type: EXPERIMENTAL
Intervention: Quinine alone
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Quinine + Fansidar
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Quinine + Tetracycline (for 10 days)
Number of subjects: 59
Study: 31575059

Group type: EXPERIMENTAL
Intervention: Low-dose POP (8.7 mg/d)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Medium-dose POP (15.2 mg/d)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-dose POP (37.2 mg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no added PS or POP)
Number of subjects: 60
Study: 28898281

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg once daily
Number of subjects: 61

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 61
Study: 25805647

Group type: EXPERIMENTAL
Intervention: 9-month intervention (physician/pharmacist collaborative model)
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: 18 and 24-month intervention (physician/pharmacist collaborative model)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 625
Study: 23662986

Group type: EXPERIMENTAL
Intervention: Prednisolone phosphate
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 21297322

Group type: EXPERIMENTAL
Intervention: Carnett's test for psychogenic abdominal pain
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Carnett's test for abdominal wall pain
Number of subjects: 130

Group type: COMPARATOR
Intervention: Carnett's test for intra-abdominal pain
Number of subjects: 130
Study: 19483236

Group type: EXPERIMENTAL
Intervention: Translocation of the proximal nerve stump into an adjacent subcutaneous vein
Number of subjects: 20

Group type: COMPARATOR
Intervention: Resection of the neuroma and translocation into muscle tissue
Number of subjects: 20
Study: 17130139

Group type: EXPERIMENTAL
Intervention: More extensive brief intervention (BI)
Number of subjects: 4008

Group type: COMPARATOR
Intervention: Minimal brief intervention (BI)
Number of subjects: 4008

Group type: EXPERIMENTAL
Intervention: Both BI types
Number of subjects: 4008
Study: 15562051

Group type: EXPERIMENTAL
Intervention: Selective spinal anesthesia (SSA) with 4 mg of hyperbaric bupivacaine
Number of subjects: 64

Group type: COMPARATOR
Intervention: General anesthesia (GA) with desflurane
Number of subjects: 64
Study: 11305522

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS) Doppler
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thermodilution technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9643792

Group type: EXPERIMENTAL
Intervention: Controlled breathing at 15 breaths per min
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Controlled breathing at 6 breaths per min
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Controlled breathing at 3 breaths per min
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1 month of respiratory training to decrease breathing rate to 6 breaths per min
Number of subjects: 50

Group type: COMPARATOR
Intervention: Spontaneous breathing (baseline)
Number of subjects: 50
Study: 7542301

Group type: EXPERIMENTAL
Intervention: Miconazole and G-CSF administered simultaneously (Group I)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Miconazole administered later during G-CSF administration (Group II)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Only miconazole administered (Group III)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Patients with neutrophil counts increased from <500/microliters to >500/microliters (Group I)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Patients with neutrophil counts increased from <500/microliters to >500/microliters (Group II)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Patients with neutrophil counts <500/microliters throughout miconazole administration (Group I)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Patients with neutrophil counts <500/microliters throughout miconazole administration (Group II)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Adverse effects in Group I
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Adverse effects in Group II
Number of subjects: 105

Group type: COMPARATOR
Intervention: Adverse effects in Group III
Number of subjects: 105
Study: 2572323

Group type: EXPERIMENTAL
Intervention: Bopindolol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 32
Study: 2008

Group type: EXPERIMENTAL
Intervention: Salicylazosulfapyridine, prednisone, and 6-mercaptopurine (alone and in combinations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (noncolitis controls)
Number of subjects: 0
Study: 30507702

Group type: EXPERIMENTAL
Intervention: Testosterone therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxandrolone in prepubertal boys
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testicular sperm extraction (TESE)
Number of subjects: 0
Study: 28170282

Group type: EXPERIMENTAL
Intervention: UD‐DPI (1.6% blend)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diskus (600 μg dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MDI (600 μg dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diskus
Number of subjects: 0

Group type: COMPARATOR
Intervention: MDI
Number of subjects: 0
Study: 26078203

Group type: EXPERIMENTAL
Intervention: Resistance training 3 days per week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Resistance training 2 days per week
Number of subjects: 30
Study: 23839182

Group type: EXPERIMENTAL
Intervention: Doxycycline calcium 0.6 mg/kg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Doxycycline calcium 1.2 mg/kg/day
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Doxycycline calcium 2.4 mg/kg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 21216540

Group type: EXPERIMENTAL
Intervention: Porcilis PCV(®) vaccine, 2 mL intramuscular dose
Number of subjects: 818

Group type: COMPARATOR
Intervention: Diluvac Forte(®) adjuvant, 2 mL intramuscular dose
Number of subjects: 818
Study: 19474425

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 127

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 127
Study: 17548839

Group type: EXPERIMENTAL
Intervention: XELOX (oral capecitabine 1,000 mg/m2 bid for 14 days plus oxaliplatin 130 mg/m2 on day 1 every 3 weeks)
Number of subjects: 348

Group type: COMPARATOR
Intervention: FUOX (continuous‐infusion FU 2,250 mg/m2 during 48 hours on days 1, 8, 15, 22, 29, and 36 plus oxaliplatin 85 mg/m2 on days 1, 15, and 29 every 6 weeks)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: XELOX
Number of subjects: 348

Group type: COMPARATOR
Intervention: FUOX
Number of subjects: 348
Study: 15157039

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 61

Group type: COMPARATOR
Intervention: Men
Number of subjects: 61
Study: 11322176

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg twice daily for 4 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg once daily for 4 days
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9478089

Group type: COMPARATOR
Intervention: Maximal inspiratory pressures in males
Number of subjects: 54

Group type: COMPARATOR
Intervention: Maximal inspiratory pressures in females
Number of subjects: 54

Group type: COMPARATOR
Intervention: Maximal expiratory pressures in males
Number of subjects: 54

Group type: COMPARATOR
Intervention: Maximal expiratory pressures in females
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Diminished peak expiratory flow in females
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Diminished peak expiratory flow in males
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Chronic bronchitis diagnosis
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Obstructive impairment of pulmonary function
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Correlation between decreased PEF and MEP in males
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Correlation between decreased PEF and MEP in females
Number of subjects: 54
Study: 7943103

Group type: EXPERIMENTAL
Intervention: Prophylactic amnioinfusion (600 ml saline solution bolus followed by 3 ml/min)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard care (including therapeutic amnioinfusion for variable decelerations)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Prophylactic amnioinfusion
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 93
Study: 3307517

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 0.01 mg/kg atropine sulphate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no atropine)
Number of subjects: 40
Study: 31338923

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus helveticus and Bifidobacterium longum)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Prebiotic (galactooligosaccharide)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 29157872

Group type: EXPERIMENTAL
Intervention: Health education intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 28539142

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham inspiratory muscle training
Number of subjects: 17
Study: 26154547

Group type: EXPERIMENTAL
Intervention: Shortened fasting with maltodextrin intake 2 hours before surgery
Number of subjects: 92
Study: 23846759

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 21704238

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300 mg (test formulation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Quetiapine XR 300 mg (reference formulation)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study: 19319953

Group type: EXPERIMENTAL
Intervention: 15 microg dose of inactivated influenza vaccine
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: 30 microg dose of inactivated influenza vaccine
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: 30 microg dose followed by 15 microg booster
Number of subjects: 815

Group type: COMPARATOR
Intervention: 15 microg dose followed by placebo
Number of subjects: 815

Group type: COMPARATOR
Intervention: 30 microg dose followed by placebo
Number of subjects: 815
Study: 17047401

Group type: EXPERIMENTAL
Intervention: Tamoxifen withdrawal
Number of subjects: 190
Study: 12767538

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 54
Study: 10838460

Group type: EXPERIMENTAL
Intervention: New human milk fortifier
Number of subjects: 29

Group type: COMPARATOR
Intervention: Reference human milk fortifier
Number of subjects: 29
Study: 9021380

Group type: EXPERIMENTAL
Intervention: 3-monthly depot leuprolide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Monthly depot leuprolide
Number of subjects: 30
Study: 1425865

Group type: EXPERIMENTAL
Intervention: lansoprazole 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: lansoprazole 20 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: lansoprazole (all doses) after 7 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: lansoprazole cessation
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study: 6438679

Group type: EXPERIMENTAL
Intervention: Pretrial smoking (Experiment I)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Posttrial smoking (Experiment I)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Pretrial smoking (Experiment II)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Posttrial smoking intervals (1, 5, and 30 min after presentation of a 20-word list) (Experiment II)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: High-nicotine cigarette (1.38 mg) (Experiment III)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Low-nicotine cigarette (0.40 mg) (Experiment III)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Smoking (Experiment IV)
Number of subjects: 94
Study: 30894213

Group type: EXPERIMENTAL
Intervention: Adoptive transfer of haploidentical natural killer (NK) cells
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (chemotherapy alone)
Number of subjects: 21
Study: 27889883

Group type: EXPERIMENTAL
Intervention: Trypsin:chymotrypsin (TC)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Serratiopeptidase (S)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Trypsin:bromelain:rutoside (TBR)
Number of subjects: 75
Study: 27213441

Group type: EXPERIMENTAL
Intervention: Restricted diet (synthetic liquid diet with 30% fewer calories and 80% less protein for five consecutive days)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: DER-diet (synthetic diet containing daily energy requirements)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study: 24465514

Group type: EXPERIMENTAL
Intervention: Belief in Heaven
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Belief in Hell
Number of subjects: 0

Group type: COMPARATOR
Intervention: Experimental priming of Hell beliefs
Number of subjects: 0
Study: 22360366

Group type: EXPERIMENTAL
Intervention: 10% sodium ascorbate (group II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 6.5% proanthocyanidin (group III)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (group I)
Number of subjects: 60
Study: 19678777

Group type: EXPERIMENTAL
Intervention: Functional water
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control mineral water
Number of subjects: 15
Study: 17474991

Group type: EXPERIMENTAL
Intervention: Daily supplementation with 11 vitamins and 5 minerals for 12 months
Number of subjects: 910

Group type: COMPARATOR
Intervention: Placebo tablet taken daily for 12 months
Number of subjects: 910
Study: 15052846

Group type: EXPERIMENTAL
Intervention: Combined treatment consisting of postisometric relaxation, massage of the prostate, and transrectal mobilization of the pelvic ligaments
Number of subjects: 106
Study: 11344184

Group type: EXPERIMENTAL
Intervention: rhGH (Saizen, Serono, Switzerland) 0.09 IU/kg body weight (BW) 3 times weekly with dietary intervention
Number of subjects: 19
Study: 9700978

Group type: EXPERIMENTAL
Intervention: 1 mg alprazolam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2 mg lorazepam
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8016771

Group type: EXPERIMENTAL
Intervention: Inhaled frusemide (40 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2736877

Group type: EXPERIMENTAL
Intervention: Lipid-supplemented group (one-quarter of glucose energy replaced by intravenous fat)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lipid-supplemented group
Number of subjects: 28

Group type: COMPARATOR
Intervention: Glucose/amino acid group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28

Group type: COMPARATOR
Intervention: Glucose-only group
Number of subjects: 28
Study: 56094

Group type: EXPERIMENTAL
Intervention: Atropine (n = 11)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Propafenone (n = 10)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Disopyramide (n = 8)
Number of subjects: 29
Study: 31550819

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery for gastric GISTs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open surgery for colorectal GISTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery for rectal GISTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopic treatment of GIST
Number of subjects: 0
Study: 28365238

Group type: EXPERIMENTAL
Intervention: Paclitaxel-Carboplatin with Necitumumab
Number of subjects: 167

Group type: COMPARATOR
Intervention: Paclitaxel-Carboplatin alone
Number of subjects: 167
Study: 25919773

Group type: EXPERIMENTAL
Intervention: Concomitant therapy (CT) - rabeprazole-amoxicillin-clarithromycin-metronidazole for 14 days; n=122
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Quadruple therapy (QT) - rabeprazole-tetracycline-metronidazole-colloidal bismuth subcitrate for 10 days; n=97
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Levofloxacin-based therapy (LT) - rabeprazole-amoxicillin-levofloxacin for 10 days; n=87
Number of subjects: 475

Group type: COMPARATOR
Intervention: Non-filling group (control)
Number of subjects: 475
Study: 23731454

Group type: EXPERIMENTAL
Intervention: 1072 nm infrared light therapy
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo (sham) light therapy
Number of subjects: 87
Study: 22085317

Group type: EXPERIMENTAL
Intervention: Remote support only
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: In-person support
Number of subjects: 415

Group type: COMPARATOR
Intervention: Control (self-directed weight loss)
Number of subjects: 415
Study: 19372480

Group type: EXPERIMENTAL
Intervention: Clear liquid gastric emptying study (300 mL of water with 7.4 MBq [0.2 mCi] of (111)In-diethylenetriaminepentaacetic acid), 30-min duration
Number of subjects: 101

Group type: COMPARATOR
Intervention: Solid gastric emptying study (standardized 4-h solid-meal study with (99m)Tc-sulfur colloid-labeled egg-substitute sandwich meal)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Normal solid emptying
Number of subjects: 101